Beamion LUNG-1: zongertinib in previously treated HER2-mutant non-small-cell lung cancer
The oral HER2-selective kinase inhibitor zongertinib shrank tumours in about seven in ten patients with previously treated HER2-mutant lung cancer with little of the diarrhoea and rash that plagued earlier HER2 pills, becoming the first oral drug approved for this driver.
Overview
Phase 1a/1b study; the primary cohort treated 75 patients with previously treated HER2 tyrosine kinase domain-mutant advanced non-small-cell lung cancer with zongertinib 120 mg daily.
Objective response was 71 percent with a median progression-free survival of 12.4 months, intracranial activity in patients with brain metastases, and mainly low-grade diarrhoea and rash; a separate cohort showed activity after prior trastuzumab deruxtecan.
- Objective response 71 percent.
- Median progression-free survival 12.4 months.
Zongertinib gives HER2-mutant lung cancer an oral targeted option with brain activity, used after platinum chemotherapy and increasingly before or after trastuzumab deruxtecan.
- Single-arm phase 1 data; first-line trials against chemo-immunotherapy are ongoing.
Similar pages
not linked directly; found by shared links- TrialBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- PersonJohn V. Heymach
Shares Beamion LUNG-1, HER2-mutant non-small-cell lung cancer.
- TrialBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati
- Key paperDESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer
Shares HER2-mutant non-small-cell lung cancer, New England Journal of Medicine.
- TermHepatotoxicity (liver enzyme elevation)
Shares Beamion LUNG-1, HER2-mutant non-small-cell lung cancer.
- TreatmentSevabertinib
- TechnologyHER2 tyrosine kinase inhibitors
Shares Beamion LUNG-1, HER2-mutant non-small-cell lung cancer.
- CompanyBoehringer Ingelheim
Shares Beamion LUNG-1, Zongertinib, HER2-mutant non-small-cell lung cancer.